Osteoarthritis: Current Concepts in Diagnosis and Management

Am Fam Physician. 2000 Mar 15;61(6):1795-1804.

Most patients with osteoarthritis seek medical attention because of pain. The safest initial approach is to use a simple oral analgesic such as acetaminophen (perhaps in conjunction with topical therapy). If pain relief is inadequate, oral nonsteroidal anti-inflammatory drugs or intra-articular injections of hyaluronic acid–like products should be considered. Intra-articular corticosteroid injections may provide short-term pain relief in disease flares. Alleviation of pain does not alter the underlying disease. Attention must also be given to nonpharmacologic measures such as patient education, weight loss and exercise. Relief of pain and restoration of function can be achieved in some patients with early osteoarthritis, particularly if an integrated approach is used. Patients with advanced disease may eventually require surgery, which generally provides excellent results.

Worldwide, osteoarthritis is the most common joint disorder. In western countries, radiographic evidence of this disease is present in the majority of persons by 65 years of age and in about 80 percent of persons more than 75 years of age.1 Approximately 11 percent of persons more than 64 years of age have symptomatic osteoarthritis of the knee.2

With the continued growth of the elderly population in the United States, osteoarthritis is becoming a major medical and financial concern. Appropriate medical management requires that physicians be able to diagnose osteoarthritis early, recognize factors that may affect the prognosis or complicate the disease, and make effective use of the many available treatments.

Pathophysiology

Biomechanical and biochemical forces are involved in cartilage destruction, which is at the core of osteoarthritis. Cytokines and growth factors are thought to play a role in the pathophysiology of the disorder. Interleukin-1 and tumor necrosis factor-β may function to activate enzymes involved in proteolytic digestion of cartilage.3 Growth factors such as tissue growth factor-β and insulin growth factor-1 may play a role in the body's attempts to repair cartilage through cartilage synthesis.4

When catabolism exceeds cartilage synthesis, osteoarthritis develops. Collagenolytic enzymes are thought to contribute to the breakdown of cartilage. Collagenase 1 (matrix metalloproteinase-1 [MMP-1]) is a fibroblast collagenase, and collagenase 2 (MMP-8) is a neutrophil collagenase. Collagenase 3 (MMP-13) may be particularly important because of its highly potent collagenolytic activity.3

Clinical Features and Diagnosis

HISTORY AND PHYSICAL EXAMINATION

The typical patient with osteoarthritis is middle-aged or elderly and complains of pain in the knee, hip, hand or spine. Most often, the patient has pain and stiffness in and around the affected joint, along with some limitation of function (Table 1).57 The symptoms are often insidious in onset.

TABLE 1

Clinical Features of Osteoarthritis

Symptoms

Joint pain

Morning stiffness lasting less than 30 minutes

Joint instability or buckling

Loss of function

Signs

Bony enlargement at affected joints

Limitation of range of motion

Crepitus on motion

Pain with motion

Malalignment and/or joint deformity

Pattern of joint involvement*

Axial: cervical and lumbar spine

Peripheral: distal interphalangeal joint, proximal interphalangeal joint, first carpometacarpal joints, knees, hips


* —Disease with multiple joint involvement is a subtype of osteoarthritis; most commonly, osteoarthritis affects the hands, hips, knees and/or spine.

Information from references 5, 6 and 7.

TABLE 1   Clinical Features of Osteoarthritis

View Table

TABLE 1

Clinical Features of Osteoarthritis

Symptoms

Joint pain

Morning stiffness lasting less than 30 minutes

Joint instability or buckling

Loss of function

Signs

Bony enlargement at affected joints

Limitation of range of motion

Crepitus on motion

Pain with motion

Malalignment and/or joint deformity

Pattern of joint involvement*

Axial: cervical and lumbar spine

Peripheral: distal interphalangeal joint, proximal interphalangeal joint, first carpometacarpal joints, knees, hips


* —Disease with multiple joint involvement is a subtype of osteoarthritis; most commonly, osteoarthritis affects the hands, hips, knees and/or spine.

Information from references 5, 6 and 7.

Pain typically worsens with use of the affected joint and is alleviated with rest. Pain at rest or nocturnal pain is a feature of severe osteoarthritis. Morning stiffness lasting less than 30 minutes is common. (In contrast, morning stiffness in patients with active rheumatoid arthritis lasts longer than 45 minutes.)

Osteoarthritis usually does not affect the wrists, elbows or shoulders. However, a less common subtype of the disease is characterized by multiple joint involvement.

Patients with osteoarthritis of the hip may complain of problems with gait. Pain can vary greatly in site and nature, which sometimes makes early diagnosis difficult. The pain may be felt in the area of the buttock, groin, thigh or knee, and it can vary in character from a dull ache to a sharp, stabbing pain. Hip stiffness is common, particularly after inactivity, and can be a presenting feature. For example, a patient may mention that a stiff hip makes it difficult to put on socks. Early physical signs of osteoarthritis of the hip include restriction of internal rotation and abduction of the affected hip, with pain occurring at the end of the range of motion.

Patients with osteoarthritis of the knee often complain of instability or buckling, especially when they are descending stairs or stepping off curbs. Patients with osteoarthritis of the hands may have problems with manual dexterity, especially if the first carpometacarpal joint is involved.

Involvement of the apophyseal or facet joints of the lower cervical spine may cause neck symptoms, and involvement of the lumbar spine may cause pain in the lower back. Osteophytes of the vertebrae can narrow the foramina and compress nerve roots. As a result, patients may have radicular symptoms, including pain, weakness and numbness of the upper extremities.

The physical examination should include a careful assessment of the affected joints, surrounding soft tissue and bursal areas. Crepitus, which is felt on passive range of motion, is due to the irregularity of opposing cartilage surfaces and is a frequent sign of osteoarthritis of the knee. Periarticular disorders, such as anserine, infrapatellar or prepatellar bursitis, should be ruled out. These disorders can be mistaken for and inappropriately treated as osteoarthritis.

Patients with erosive osteoarthritis may have signs of inflammation in the interphalangeal joints of the hands. This inflammation can be mistaken for rheumatoid arthritis, which causes similar proximal interphalangeal joint swelling. However, osteoarthritis generally does not have an inflammatory component, except in advanced disease. The presence of a hot, erythematous, markedly swollen joint suggests a septic joint or a crystal arthropathy such as gout, pseudogout or hydroxyapatite arthritis.

RADIOGRAPHIC FEATURES AND LABORATORY FINDINGS

Radiographs can usually confirm the diagnosis of osteoarthritis, although the findings are nonspecific. The cardinal radiographic features of the disease are a loss of joint space and the presence of new bone formation or osteophytes. The association between joint pain and the radiographic features of osteoarthritis is not constant, in that many joints with pathologic or radiographic evidence of this disease remain asymptomatic. Because bone demineralization is not a radiographic feature of osteoarthritis, its presence strongly suggests an inflammatory condition such as rheumatoid arthritis.

Most routine blood tests are normal in patients with uncomplicated osteoarthritis. Analysis of synovial fluid usually reveals a white blood cell count of less than 2,000 per mm3 (2.0 × 109 per L).

Osteoarthritis secondary to a metabolic, genetic or other joint disorder should be suspected in the patient with widespread disease, a prominent inflammatory component, an unusual joint distribution or disease onset before 50 years of age. If the diagnosis of osteoarthritis is in doubt, consultation with a rheumatologist should be sought.

The American College of Rheumatology (ACR) has developed diagnostic criteria for osteoarthritis at various sites, including the hip (Table 2),5  the knee (Table 3)6  and the hand (Table 4).7

TABLE 2

Classification Criteria for Osteoarthritis of the Hip

Traditional format

Hip pain plus at least two of the following:

ESR of less than 20 mm per hour

Femoral or acetabular osteophytes on radiographs

Joint space narrowing on radiographs

Classification-tree format

Hip pain plus femoral or acetabular osteophytes on radiographs

or

Hip pain plus joint space narrowing on radiographs and an ESR of less than 20 mm per hour


ESR = erythrocyte sedimentation rate.

Adapted with permission from Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505–14.

TABLE 2   Classification Criteria for Osteoarthritis of the Hip

View Table

TABLE 2

Classification Criteria for Osteoarthritis of the Hip

Traditional format

Hip pain plus at least two of the following:

ESR of less than 20 mm per hour

Femoral or acetabular osteophytes on radiographs

Joint space narrowing on radiographs

Classification-tree format

Hip pain plus femoral or acetabular osteophytes on radiographs

or

Hip pain plus joint space narrowing on radiographs and an ESR of less than 20 mm per hour


ESR = erythrocyte sedimentation rate.

Adapted with permission from Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991;34:505–14.

TABLE 3

Classification Criteria for Idiopathic Osteoarthritis of the Knee

Traditional format

Knee pain plus osteophytes on radiographs and at least one of the following:

Patient age older than 50 years

Morning stiffness lasting 30 minutes or less

Crepitus on motion

Classification-tree format

Knee pain and osteophytes on radiographs

or

Knee pain plus patient age of 40 years or older, morning stiffness lasting 30 minutes or less and crepitus on motion


Adapted with permission from Altman R, Asch E, Bloch D, Bole D, Borenstein K, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039–49.

TABLE 3   Classification Criteria for Idiopathic Osteoarthritis of the Knee

View Table

TABLE 3

Classification Criteria for Idiopathic Osteoarthritis of the Knee

Traditional format

Knee pain plus osteophytes on radiographs and at least one of the following:

Patient age older than 50 years

Morning stiffness lasting 30 minutes or less

Crepitus on motion

Classification-tree format

Knee pain and osteophytes on radiographs

or

Knee pain plus patient age of 40 years or older, morning stiffness lasting 30 minutes or less and crepitus on motion


Adapted with permission from Altman R, Asch E, Bloch D, Bole D, Borenstein K, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039–49.

TABLE 4

Classification Criteria for Osteoarthritis of the Hand

Hand pain, aching or stiffness

plus

Hard tissue enlargement of two or more of 10 selected joints*

plus

Fewer than three swollen metacarpophalangeal joints

plus

Hard tissue enlargement of two or more distal interphalangeal joints

or

Deformity of two or more of 10 selected joints*


* —The 10 selected joints are the second and third distal interphalangeal joints, the second and third proximal interphalangeal joints and the first carpometacarpal joints (of both hands).

Adapted with permission from Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein K, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601–10.

TABLE 4   Classification Criteria for Osteoarthritis of the Hand

View Table

TABLE 4

Classification Criteria for Osteoarthritis of the Hand

Hand pain, aching or stiffness

plus

Hard tissue enlargement of two or more of 10 selected joints*

plus

Fewer than three swollen metacarpophalangeal joints

plus

Hard tissue enlargement of two or more distal interphalangeal joints

or

Deformity of two or more of 10 selected joints*


* —The 10 selected joints are the second and third distal interphalangeal joints, the second and third proximal interphalangeal joints and the first carpometacarpal joints (of both hands).

Adapted with permission from Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein K, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990;33:1601–10.

Treatment

Treatment of osteoarthritis should be individualized. Comorbid conditions such as cardiac disease, hypertension, peptic ulcer disease or renal disease must be considered, and the patient's needs and expectations should also be taken into account. An algorithm for the management of osteoarthritis of the knee is presented in Figure 1,8,9 and an algorithm for the management of osteoarthritis of the hip is provided in Figure 2.9,10

Management of Osteoarthritis of the Knee

FIGURE 1.

An algorithm for the suggested management of osteoarthritis of the knee. (NSAID = nonsteroidal anti-inflammatory drug)

Adapted with permission from Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6, and Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med 1997;103:25S–30S.

View Large

Management of Osteoarthritis of the Knee


FIGURE 1.

An algorithm for the suggested management of osteoarthritis of the knee. (NSAID = nonsteroidal anti-inflammatory drug)

Adapted with permission from Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6, and Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med 1997;103:25S–30S.

Management of Osteoarthritis of the Knee


FIGURE 1.

An algorithm for the suggested management of osteoarthritis of the knee. (NSAID = nonsteroidal anti-inflammatory drug)

Adapted with permission from Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum 1995;38:1541-6, and Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med 1997;103:25S–30S.

Management of Osteoarthritis of the Hip

FIGURE 2.

An algorithm for the suggested management of osteoarthritis of the hip. (NSAID = nonsteroidal anti-inflammatory drug)

Adapted with permission from Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med 1997;103:25S-30S, and Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995;38:1535-40.

View Large

Management of Osteoarthritis of the Hip


FIGURE 2.

An algorithm for the suggested management of osteoarthritis of the hip. (NSAID = nonsteroidal anti-inflammatory drug)

Adapted with permission from Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med 1997;103:25S-30S, and Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995;38:1535-40.

Management of Osteoarthritis of the Hip


FIGURE 2.

An algorithm for the suggested management of osteoarthritis of the hip. (NSAID = nonsteroidal anti-inflammatory drug)

Adapted with permission from Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med 1997;103:25S-30S, and Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum 1995;38:1535-40.

NONPHARMACOLOGIC MANAGEMENT

Patient Education. Arthritis self-help courses conducted by allied health professionals teach patients how to manage their disease. Participation in such courses has been associated with decreased pain and improved quality of life.8,1012

Local chapters of the Arthritis Foundation administer self-help courses for patients with osteoarthritis. Educational materials to help patients better understand and cope with osteoarthritis can also be obtained from the Arthritis Foundation (Web site: http://www.arthritis.org; telephone: 888-879-7890).

Regular patient contact has also been shown to be valuable in the management of osteoarthritis. One study found that monthly telephone communications with patients were cost-effective and were associated with good clinical outcomes.13

Exercise. Patients are often concerned that joint use will “wear out” a damaged joint. However, the available evidence shows that regular low-impact exercise of osteoarthritic joints does not increase the development of osteoarthritis.14,15

The goals of an exercise program are to maintain range of motion, muscle strength and general health. All patients with osteoarthritis of the knee should be taught quadriceps-strengthening exercises and should be encouraged to perform them every day.

Patients may also be referred to aerobic exercise programs such as fitness walking or swimming. Patients with osteoarthritis who participate in an aerobic exercise program have been shown to have improved aerobic capacity and 50-ft walking times, as well as decreased depression and anxiety, compared with patients who only perform range-of-motion exercises.16

Assistive Devices. Many patients with osteoarthritis of the hip and knee are more comfortable wearing shoes with good shock-absorbing properties or orthoses.

The use of an appropriately selected cane can reduce hip loading by 20 to 30 percent.17 Attention must be given to the length of the cane and how it is to be used. The top of the cane's handle should reach the patient's proximal wrist crease when the patient is standing with arms at the side. The cane is usually held on the unaffected side of the body.

Patients with specific physical disabilities may benefit from physical and occupational therapy. The physical therapist can provide an individualized exercise program and teach the patient how to use therapeutic heat and massage. An occupational therapist can determine whether the patient needs assistive devices such as a raised toilet seat. In addition, special splints can be designed to stabilize or reduce inflammation of particular joints, such as the first carpometacarpal joint or the base of the thumb.

Weight Management. There is a longitudinal association between obesity and osteoarthritis of the knee in men and women, although obesity is a greater risk factor in women.18 Therefore, primary preventive strategies may include measures to avoid weight gain, or to achieve weight loss in overweight patients. It is not clear whether weight loss will improve symptoms in patients who are already experiencing symptoms of osteoarthritis of the knee.19 Further studies are needed to determine if weight loss has a role in the tertiary prevention of osteoarthritis.

Supplements. The lay media and books have widely proclaimed dietary supplements such as glucosamine sulfate and chondroitin sulfate to be “cures” for arthritis. Although small trials conducted in Europe and the United States showed some efficacy for these agents,20,21 the trials were flawed in design and included few patients.

Randomized controlled trials are currently being conducted to determine whether glucosamine sulfate and chondroitin sulfate are safe, tolerated and effective in patients with osteoarthritis. At present, these supplements cannot be recommended for use in the treatment of osteoarthritis.

PHARMACOLOGIC TREATMENTS

Simple Analgesics. A large number of medicines are prescribed for and consumed by patients with osteoarthritis, largely for the relief of pain. The recognition that pain in osteoarthritis is not necessarily due to inflammation has led to an increased awareness of the role of simple analgesics in the treatment of this disease.

The ACR guidelines emphasize the use of acetaminophen as first-line treatment for osteoarthritis of the hip and knee.810 One randomized, double-blind, crossover trial showed that, compared with placebo, acetaminophen in a dosage of 4 g per day significantly relieved pain and improved function in patients with osteoarthritis of the knee.22

Opioid-containing analgesics, including codeine and propoxyphene (Darvon), can be used for short periods to treat exacerbations of pain. These agents are not recommended for prolonged use because they cause constipation and increase the risk of falling, particularly in the elderly.

Nonsteroidal Anti-inflammatory Drugs (NSAIDs). Trials comparing simple analgesics and NSAIDs found that acetaminophen alone can control pain in a substantial number of patients with osteoarthritis.2325 In patients requiring NSAID therapy, concurrent use of acetaminophen may allow the NSAID dosage to be reduced, thereby limiting toxicity. In the individual patient, cost, dosing frequency and medication tolerance may influence NSAID selection.

If an NSAID is to be used, safety is an important issue, especially in the elderly. The risk of NSAID-induced renal and hepatic toxicity is increased in older patients and in patients with preexisting renal or hepatic insufficiency. Thus, it is important to monitor renal and liver function. Nonacetylated salicylates such as choline magnesium trisalicylate (Trilisate) and salsalate (Disalcid) cause less renal toxicity.26

The authors of this article recommend that liver function tests and serum hemoglobin, creatinine and potassium measurements be performed before NSAID therapy is initiated and again after six months of treatment. Several factors appear to increase the risk of NSAID-induced gastropathy (Table 5).27

TABLE 5

Risk Factors for Ulcer Complications Induced by Nonsteroidal Anti-inflammatory Drugs

Definite risk factors

Patient older than 65 years of age

Previous ulcer disease or upper gastrointestinal tract bleeding

Use of multiple nonsteroidal anti-inflammatory drugs or use of a high dosage of one of these drugs

Concomitant oral corticosteroid therapy

Concomitant anticoagulant therapy

Duration of therapy (risk is higher in first three months of treatment)

Possible risk factors

Female gender

Smoking

Alcohol consumption

Helicobacter pylori infection


Adapted with permission from Lichtenstein DR, Syngal S, Wolfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995;38:5–18.

TABLE 5   Risk Factors for Ulcer Complications Induced by Nonsteroidal Anti-inflammatory Drugs

View Table

TABLE 5

Risk Factors for Ulcer Complications Induced by Nonsteroidal Anti-inflammatory Drugs

Definite risk factors

Patient older than 65 years of age

Previous ulcer disease or upper gastrointestinal tract bleeding

Use of multiple nonsteroidal anti-inflammatory drugs or use of a high dosage of one of these drugs

Concomitant oral corticosteroid therapy

Concomitant anticoagulant therapy

Duration of therapy (risk is higher in first three months of treatment)

Possible risk factors

Female gender

Smoking

Alcohol consumption

Helicobacter pylori infection


Adapted with permission from Lichtenstein DR, Syngal S, Wolfe MM. Non-steroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum 1995;38:5–18.

When used as cotherapy in patients requiring chronic NSAID treatment, misoprostol (Cytotec), a synthetic prostaglandin E1 analog, helps to prevent gastric ulcers.27 Omeprazole (Prilosec), a proton pump inhibitor, appears to be as effective as misoprostol in healing NSAID-induced ulcers and erosions, and it has the advantage of once-daily dosing.28 Hisamine-H2 blockers such as ranitidine (Zantac) can prevent duodenal ulcers in patients receiving chronic NSAID therapy; however, ranitidine is ineffective in preventing gastric ulcers.27

The ACR provides no specific guidelines for the prevention and treatment of active ulcer disease and its complications in patients with osteoarthritis who are receiving NSAIDs.10

New Developments. The presently available NSAIDs work through nonspecific inhibition of cyclooxygenase isoforms 1 and 2 (COX-1 and COX-2). COX-1 is expressed in gastric and renal tissues (among others), whereas COX-2 is inducible and is part of the inflammatory response.29

Celecoxib (Celebrex) is the first COX-2 inhibitor labeled by the U.S. Food and Drug Administration (FDA) for the treatment of osteoarthritis and rheumatoid arthritis. In a recent study, celecoxib effectively alleviated pain and reduced inflammation but showed no evidence of inducing gastric ulcers or affecting platelet function (two toxic effects associated with COX-1 inhibitors).30 Although the risk of gastrointestinal bleeding is low, physicians should remain vigilant for signs of gastrointestinal bleeding. The most common side effects of celecoxib are dyspepsia, diarrhea and abdominal pain.

An additional COX-2 inhibitor, rofecoxib (Vioxx), has also been labeled as a once-daily medication for the treatment of osteoarthritis and acute pain. Clinical trials showed that rofecoxib was as effective as ibuprofen and diclofenac and was significantly superior to placebo in the treatment of pain in patients with osteoarthritis.31,32

Local Analgesics. Capsaicin (e.g., ArthriCare), a pepper-plant derivative, has been shown to be better than placebo in relieving the pain of osteoarthritis. One double-blind randomized, controlled trial showed that 0.025 percent capsaicin cream applied four times daily was effective in the management of pain caused by osteoarthritis of the knee, ankle, wrist and shoulder.33 The improvement in pain was measured by visual analog scales.

Another trial found that patients with osteoarthritis or rheumatoid arthritis who were receiving conventional therapy generally experienced substantial diminution of pain following application of capsaicin cream to the affected joint.34 Capsaicin appears to be an important adjunctive treatment for disease flares in osteoarthritis.

Capsaicin cream is available over the counter in concentrations of 0.025, 0.075 and 0.25 percent. One common side effect is a local burning sensation. Patients should be advised to apply capsaicin cream with a glove to prevent inadvertent spread to the eyes or other mucous membranes.

Intra-articular Corticosteroid Injections. Patients with a painful flare of osteoarthritis of the knee may benefit from intra-articular injection of a corticosteroid such as methylprednisolone (Medrol) or triamcinolone (Aristocort).35,36 When a joint is painful and swollen, short-term pain relief can be achieved with aspiration of joint fluid followed by intra-articular injection of a corticosteroid.

A joint should not be injected more than three or four times in one year because of the possibility of cartilage damage from repeated injections. Patients who require more than three or four injections per year to control symptoms are probably candidates for surgical intervention.

Patients with painful osteoarthritis of the hip may benefit from intra-articular corticosteroid injections. These injections should be performed under fluoroscopic guidance.10

Intra-articular Injections of Hyaluronic Acid–Like Products. Hyaluronic acid is a major nonstructural component of the synovial and cartilage extracellular matrix. It confers viscoelastic and lubricating properties to the joint. In patients with osteoarthritis, the concentration and the molecular weight of hyaluronic acid are decreased. Thus, viscosupplementation with hyaluronic acid–like products is thought to be a possible treatment for osteoarthritis.

The FDA has labeled sodium hyaluronate (Hyalgan) and hylan G-F 20 (Synvisc) injections for the treatment of pain caused by osteoarthritis of the knee. One study on intra-articular hyaluronate injections in osteoarthritis of the knee found no difference in pain, function or global evaluation between treatment and placebo groups.37 However, the hyaluronate injections did reduce pain in a subgroup of patients more than 60 years of age who had more severe disease.

Another study found that when used as a replacement or an adjunct for NSAID therapy in patients with osteoarthritis of the knee, hylan G-F 20 injections were at least as effective as continuous NSAID therapy in all outcome measures except activity restriction.38

SURGERY

Patients whose symptoms are not adequately controlled with medical therapy and who have moderate to severe pain and functional impairment are candidates for orthopedic surgery. Osteoarthritis of the knee that is complicated by internal derangement may be treated with arthroscopic debridement or joint lavage. Osteotomy may be performed if significant malalignment of the knee or hip joints is present. Total joint arthroplasty usually has an excellent outcome and markedly improves quality of life.39

FUTURE DIRECTIONS

Most investigational therapies are targeted toward the inhibition of collagenolytic enzymes using, for example, oral doxycycline (Vibramycin) or specific metalloproteinase inhibitors. Other developments include tissue engineering using autologous chondrocytes cultured in vitro and reintroduced into the joint. The clinical applications of these approaches are currently limited to research settings.

The Authors

NISHA J. MANEK, M.D., M.R.C.P., is a fellow in the immunology and rheumatology division at Stanford University Medical Center, Palo Alto, Calif. Dr. Manek graduated from the Faculty of Medicine at the University of Glasgow, Scotland, and completed a residency in internal medicine at Loma Linda (Calif.) University Medical Center.

NANCY E. LANE, M.D., is associate professor of medicine and rheumatology at the University of California, San Francisco, School of Medicine, where she earned her medical degree. Dr. Lane completed a residency in internal medicine at UCSF Mount Zion Medical Center, San Francisco, and a fellowship in rheumatology at Stanford University Medical Center.

Address correspondence to Nancy E. Lane, M.D., Division of Rheumatology, Box 0868, University of California, San Francisco, School of Medicine, San Francisco, CA 94143. Reprints are not available from the authors.

Dr. Lane has received grants or research support from Chiron Corporation, Wyeth-Ayerst Laboratories, and Procter and Gamble Pharmaceuticals. She has also been on the speakers bureaus of Merck and Co., Wyeth-Ayerst Laboratories, and Hoechst Marion Roussel.

REFERENCES

1. Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger TA Jr, Felts WR, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol. 1989;16:427–41.

2. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41:1343–55.

3. Pelletier JP, DiBattista JA, Roughley P, McCollum R, Martel-Pelletier J. Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am. 1993;19:545–68.

4. Malemud CJ. The role of growth factors in cartilage metabolism. Rheum Dis Clin North Am. 1993;19:569–80.

5. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum. 1991;34:505–14.

6. Altman R, Asch E, Bloch D, Bole D, Borenstein K, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum. 1986;29:1039–49.

7. Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein K, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990;33:1601–10.

8. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38:1541–6.

9. Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med. 1997;103:25S–30S.

10. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, et al. Guidelines for the medical management of osteoarthritis. Part I. Osteoarthritis of the hip. American College of Rheumatology. Arthritis Rheum. 1995;38:1535–40.

11. Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum. 1993;36:439–46.

12. Lorig KR, Lubeck D, Kraines RG, Seleznick M, Holman HR. Outcomes of self-help education for patients with arthritis. Arthritis Rheum. 1985;28:680–5.

13. Weinberger M, Tierney WM, Cowper PA, Katz BP, Booher PA. Cost-effectiveness of increased telephone contact for patients with osteoarthritis. A randomized, controlled trial. Arthritis Rheum. 1993;36:243–6.

14. Kovar PA, Allegrante JP, MacKenzie CR, Peterson MG, Gutin B, Charlson ME. Supervised fitness walking in patients with osteoarthritis of the knee. A randomized, controlled trial. Ann Intern Med. 1992;116:529–34.

15. Lane NE. Exercise: a cause of osteoarthritis. J Rheumatol. 1995;22(suppl 43):3–6.

16. Minor MA, Hewett JE, Webel RR, Anderson SK, Kay DR. Efficacy of physical conditioning exercise in patients with rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 1989;32:1396–405.

17. Blount WP. Don't throw away the cane. J Bone Joint Surg [Am]. 1956;38:695–8.

18. Felson DT, Anderson JJ, Naimark A, Walker AM, Meenan RF. Obesity and knee osteoarthritis. The Framingham Study. Ann Intern Med. 1988;109:18–24.

19. Felson DT, Zhang Y, Anthony JM, Naimark A, Anderson JJ. Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med. 1992;116:535–9.

20. Morreale P, Manopulo R, Galati M, Boccanera L, Saponati G, Bocchi L. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol. 1996;23:1385–91.

21. Müller-Fassbender H, Bach GL, Haase W, Rovati LC, Setnikab I. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage. 1994;2:61–9.

22. Amadio P, Cummings DM. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Curr Ther Res. 1983;34:59–66.

23. March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P. n of 1 trials comparing a non-steroidal anti-inflammatory drug with paracetamol in osteoarthritis. BMJ. 1994;309:1041–5.

24. Williams HJ, Ward JR, Egger MJ, Neuner R, Brooks RH, Clegg DO, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum. 1993;36:1196–206.

25. Bradley JD, Brandt KD, Katz BP, Kalasinski LA, Ryan SI. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325:87–91.

26. Furst DE. Are there differences among nonsteroidal antiinflammatory drugs? Comparing acetylated salicylates, nonacetylated salicylates, and nonacetylated nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1994;37:1–9.

27. Lichtenstein DR, Syngal S, Wolfe MM. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. The double-edged sword. Arthritis Rheum. 1995;38:5–18.

28. Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-Induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727–34.

29. Lane NE. Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol. 1997;24(suppl 49):20–4.

30. Simon LS, Lanza FL, Lipsky PE, Hubbard RC, Talwalker S, Schwartz BD, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591–602.

31. Scott LJ, Lamb HM. Rofecoxib. Drugs. 1999;58:499–505.

32. Ehrich EW, Schnitzer TJ, McIlwain H, Levy R, Wolfe F, Weisman M, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol. 1999;26:2438–47.

33. Altman RD, Auen A, Holmburg CE, Pfeifer LM, Sack M, Young GT. Capsaicin cream 0.025% as monotherapy for osteoarthritis: a double-blind study. Semin Arthritis Rheum. 1994;23(suppl 3):S25–33.

34. Deal CL, Schnitzer TJ, Lipstein E, Seibold JR, Stevens RM, Levy MD, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther. 1991;13:383–95.

35. Freidman DM, Moore ME. The efficacy of intra-articular steroids in osteoarthritis: a double-blind study. J Rheumatol. 1980;7:850–6.

36. Dieppe PA, Sathapatayavongs B, Jones HE, Bacon PA, Ring EF. Intra-articular steroids in osteoarthritis. Rheumatol Rehabil. 1980;19:212–7.

37. Lohmander LS, Dalen N, Englund G, Hamalainen M, Jensen EM, Karlsson K, et al. Intra-articular hyaluronan injections in the treatment of osteoarthritis of the knee: a randomised, double blind, placebo controlled multicentre trial. Hyaluronan Multicentre Trial Group. Ann Rheum Dis. 1996;55:424–31.

38. Adams ME, Atkinson MH, Lussier AJ, Schulz JI, Siminovitch KA, Wade JP, et al. The role of visco-supplementation with hylan G-F 20 (Synvisc) in the treatment of osteoarthritis of the knee: a Canadian multicenter trial comparing hylan G-F 20 alone, hylan G-F 20 with non-steroidal anti-inflammatory drugs (NSAIDs) and NSAIDs alone. Osteoarthritis & Cartilage. 1995;3:213–25.

39. Buckwalter JA, Lohmander S. Operative treatment of osteoarthritis. Current practice and future development. J Bone Joint Surg [Am]. 1994;76:1405–18.


Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article